17 studies found for:    Open Studies | spectrum pharmaceuticals
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | spectrum pharmaceuticals
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Not yet recruiting To Evaluate the Safety and Pharmacokinetics of Belinostat in Patients Who Have Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
Conditions: Solid Tumors;   Hematological Malignancies
Interventions: Drug: Belinostat IV;   Drug: Belinostat
2 Not yet recruiting To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.
Condition: Relapsed/Refractory Solid Tumors/Hematological Malignancies
Intervention: Drug: Belinostat
3 Not yet recruiting Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Poziotinib
4 Recruiting RAnDomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCEr Patients Receiving Docetaxel and Cyclophosphamide
Conditions: Neutropenia;   Breast Cancer
Interventions: Drug: SPI-2012;   Drug: Pegfilgrastim
5 Recruiting A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)
Condition: Peripheral T-Cell Lymphoma (PTCL)
Intervention: Drug: Pralatrexate Injection
6 Recruiting A Study of Intravesical Apaziquone as a Surgical Adjuvant in Patient Undergoing TURBT
Condition: Bladder Cancer
Interventions: Drug: Apaziquone;   Other: Placebo
7 Recruiting Phase 2, Single Arm, Open Label Study of Folotyn in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With PTCL
Conditions: Relapsed Peripheral T-Cell Lymphoma;   Refractory Peripheral T-Cell Lymphoma
Interventions: Drug: Folotyn and Leucovorin;   Drug: Folic Acid;   Drug: Vitamin B12
8 Recruiting Zevalin Post-marketing Surveillance in Japan
Condition: Non-Hodgkin's Lymphoma (NHL)
Intervention: Drug: [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)
9 Not yet recruiting Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma, Follicular;   Lymphoma, Mantle-Cell;   Lymphoma, Small-Cell;   Waldenstrom Macroglobulinemia;   Lymphoma, B-Cell, Marginal Zone
Interventions: Drug: Rituximab;   Drug: Bendamustine;   Drug: Vincristine sulfate liposome injection
10 Recruiting MRSI to Predict Response to RT/TMZ ± Belinostat in GBM
Condition: Glioblastoma Multiforme of Brain
Interventions: Radiation: Standard Radiation Therapy;   Drug: Standard Temozolomide;   Drug: Belinostat
11 Recruiting Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Conditions: Refractory Non Hodgkin Lymphoma;   Relapsed Non Hodgkin Lymphoma
Interventions: Biological: rituximab;   Biological: ibritumomab tiuxetan;   Biological: anti-thymocyte globulin;   Radiation: total nodal irradiation;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
12 Recruiting Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
Conditions: Leukemia;   Lymphoma
Interventions: Drug: Rituximab;   Drug: 111In Ibritumomab;   Procedure: Planar Scintigraphy Imaging;   Drug: 90Y IbritumomabTiuxetan;   Drug: Fludarabine;   Drug: Bendamustine;   Drug: Thymoglobulin;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Mycophenolate;   Drug: G-CSF;   Procedure: Stem Cell Transplantation
13 Recruiting Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
Condition: Leukemia
Interventions: Drug: Rituximab;   Drug: Imatinib;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Mesna;   Drug: VSLI;   Drug: Solu-Medrol;   Drug: Methotrexate;   Drug: Ara-C;   Drug: G-CSF;   Drug: Pegfilgrastim;   Drug: Dexamethasone
14 Recruiting Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis
Condition: Hematological Malignancy
Interventions: Drug: Cohort 1-Bortezomib (Velcade ®);   Drug: Cohort 2-Bortezomib (Velcade ®);   Drug: Cohort 3-Bortezomib (Velcade ®)
15 Recruiting Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission
Condition: Neuroblastoma
Intervention: Drug: DFMO
16 Recruiting Behavioral Treatment of Adolescent Substance Use
Condition: Substance Use Disorders
Interventions: Behavioral: Behavior Therapy;   Behavioral: Working Memory Training
17 Recruiting Pheno- & Genotyping POF (WHO III)
Conditions: Premature Ovarian Failure (POF);   Incipient Ovarian Failure;   Poor Response After Ovarian Hyperstimulation;   Early Menopause;   Hypergonadotropic Amenorrhea
Intervention:

Indicates status has not been verified in more than two years